Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $6.6 million.

  • Century Therapeutics' Treasury Shares rose 6113.62% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 6113.62%. This contributed to the annual value of $2.9 million for FY2024, which is 2333.92% down from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Treasury Shares is $6.6 million, which was up 6113.62% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Treasury Shares registered a high of $6.6 million during Q3 2025, and its lowest value of $49416.0 during Q2 2023.
  • For the 4-year period, Century Therapeutics' Treasury Shares averaged around $2.1 million, with its median value being $520630.0 (2022).
  • Per our database at Business Quant, Century Therapeutics' Treasury Shares tumbled by 9049.9% in 2023 and then skyrocketed by 821555.44% in 2024.
  • Century Therapeutics' Treasury Shares (Quarter) stood at $193031.0 in 2022, then tumbled by 74.4% to $49416.0 in 2023, then surged by 5673.25% to $2.9 million in 2024, then soared by 132.32% to $6.6 million in 2025.
  • Its Treasury Shares was $6.6 million in Q3 2025, compared to $4.1 million in Q2 2025 and $4.7 million in Q1 2025.